How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

Video Library —July 18, 2018
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Director, Thoracic Oncology Research Program Associate Director for Translational
Research Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
David L Rimm, MD, PhD
Professor of Pathology and Medicine (Oncology)
Yale University School of Medicine
New Haven, CT
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
Related Articles
Building an Award-Winning Local Navigator Network
October 2019 Vol 10, No 10
An Interview with Donna Moore Wilson, RN, MSN, CBCN, of the Virginia Cancer Patient Navigator Network
The CAPE Initiative: Developing Meaningful Educational Materials to Elevate Quality of Life for Patients with Lung Cancer
July 2019 Vol 10, No 7
An Interview with Cheryl Bellomo, MSN, RN, OCN, ONN-CG, and Amy Jo Pixley, MSN, RN, OCN, ONN-CG(T)
An Interview with Gregory C. Simon, JD, About the Biden Cancer Initiative’s Strategies to Improve Cancer Care
Kristin Siyahian
|
March 2019 Vol 10, No 3
Last modified: August 30, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code